Actively Recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Deurremidevir Hydrobromide Oral Suspension in Infants and Young Children With Respiratory Syncytial Virus Infection
Led by Simcere Pharmaceutical Co., Ltd · Updated on 2026-04-02
498
Participants Needed
4
Research Sites
13 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the safety and effectiveness of Deurremidevir Hydrobromide oral suspension in infants and young children aged 1 to 36 months who have respiratory syncytial virus (RSV) infection. This Phase III randomized, double-blind, placebo-controlled trial aims to understand how this investigational drug affects RSV symptoms and disease recovery compared to placebo. The trial is sponsored by Simcere Pharmaceutical Co., Ltd and will enroll about 498 participants. Participants will be randomly assigned in a 2:1 ratio to receive either Deurremidevir Hydrobromide (called SIM0916) or a placebo. The drug dose is adjusted by weight, given at 20 mg per kilogram three times daily for five consecutive days, totaling 15 doses. The study monitors participants through this treatment period, comparing outcomes between the drug and placebo groups. During the study, infants and children will be regularly assessed for RSV-related clinical signs and symptoms, including wheezing and cough, using scores like the Wang Bronchiolitis Score. Researchers will track recovery times and the need for intensive care or respiratory support. Safety and symptom resolution will be followed up to day 26 after the first dose. The total participation duration covers screening, treatment, and follow-up assessments to evaluate the drug's impact and monitor safety.
CONDITIONS
Brief Title
A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Infants and young children aged 1 to 36 months, any gender
- Weight between 2.5 kg and 20 kg
- Positive RSV antigen or nucleic acid test
- Illness duration due to RSV infection of 96 hours or less
- Presence of tachypnea (rapid breathing) and wheezing
- Wang Bronchiolitis Score of 5 or higher
- For children under 12 months, head circumference within normal range for age and gender
You will not qualify if you...
- Use of prohibited medications specified by the study protocol
- Severe lung or other organ complications
- Need for vasopressors or inotropic agents
- Known concurrent infections like SARS-CoV-2, influenza, Mycoplasma, bacterial or other pathogens
- History of high carbon dioxide levels (hypercapnia)
- Chronic or persistent feeding difficulties
- Gastrointestinal diseases affecting drug absorption
- Congenital metabolic disorders
- Bronchopulmonary dysplasia requiring assisted ventilation or significant congenital respiratory abnormalities
- Congenital heart disease affecting study evaluation
- Signs of liver failure or abnormal liver tests
- Kidney failure or abnormal kidney tests
- Known or suspected HIV infection
- Primary immune deficiencies or transplant recipients
- History of epilepsy or febrile convulsions
- Personal or family history of severe allergies
- Active or uncontrolled serious diseases of the lungs, heart, liver, brain, kidneys, or others deemed unsuitable by the investigator
- Participation in other clinical trials with investigational drugs or devices
- Other reasons deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 26 days
Participants receive either Deuremidevir Hydrobromide oral suspension or placebo to treat RSV infection.
Daily visits or assessments during treatment period
Trial Site Locations
Total: 4 locations
1
The First Affiliated Hospital Of Xiamen University
Xiamen, Fujian, China
Actively Recruiting
2
Hunan Children's Hospital
Changsha, Hunan, China
Actively Recruiting
3
West China Second University Hospital Sichuan University
Chengdu, Sichuan, China
Not Yet Recruiting
4
Shulan(hangzhou)Hospital
Hangzhou, Zhejiang, China
Not Yet Recruiting
Research Team
Z
zhibiao song
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here